Seoulin Bioscience Co.Ltd (038070) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.007x

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has a cash flow conversion efficiency ratio of 0.007x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩631.76 Million ≈ $428.14K USD) by net assets (₩86.05 Billion ≈ $58.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Seoulin Bioscience Co.Ltd market capitalisation for the company's overall valuation and market capitalisation.

Seoulin Bioscience Co.Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Seoulin Bioscience Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Seoulin Bioscience Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their cash flow conversion efficiency. Explore Seoulin Bioscience Co.Ltd (038070) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Bintang Mitra Semestaraya Tbk JK:BMSR	0.027x
Earlypay Ltd AU:EPY	0.071x
EV Resources Ltd AU:EVR	-0.137x
SD SYSTEM Co. Ltd KQ:121890	-0.170x
The Century Co., Ltd. KO:002420	0.002x
Zee Learn Limited NSE:ZEELEARN	0.024x
Vikas Lifecare Limited NSE:VIKASLIFE	0.003x
Damai Sejahtera Abadi Tbk PT JK:UFOE	0.101x

Annual Cash Flow Conversion Efficiency for Seoulin Bioscience Co.Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Seoulin Bioscience Co.Ltd from 2013 to 2025. View latest Seoulin Bioscience Co.Ltd stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩86.05 Billion ≈ $58.32 Million	₩4.76 Billion ≈ $3.23 Million	0.055x	+200.62%
2024-12-31	₩83.89 Billion ≈ $56.85 Million	₩-4.61 Billion ≈ $-3.13 Million	-0.055x	-590.65%
2023-12-31	₩83.06 Billion ≈ $56.29 Million	₩930.57 Million ≈ $630.63K	0.011x	+121.55%
2022-12-31	₩83.79 Billion ≈ $56.78 Million	₩-4.36 Billion ≈ $-2.95 Million	-0.052x	-143.64%
2021-12-31	₩74.86 Billion ≈ $50.73 Million	₩8.92 Billion ≈ $6.04 Million	0.119x	+93.73%
2020-12-31	₩59.92 Billion ≈ $40.61 Million	₩3.68 Billion ≈ $2.50 Million	0.061x	-49.85%
2019-12-31	₩59.71 Billion ≈ $40.46 Million	₩7.32 Billion ≈ $4.96 Million	0.123x	+57.79%
2018-12-31	₩53.72 Billion ≈ $36.40 Million	₩4.17 Billion ≈ $2.83 Million	0.078x	+207.51%
2017-12-31	₩51.49 Billion ≈ $34.90 Million	₩1.30 Billion ≈ $881.84K	0.025x	-55.42%
2016-12-31	₩48.60 Billion ≈ $32.94 Million	₩2.76 Billion ≈ $1.87 Million	0.057x	-37.62%
2015-12-31	₩45.30 Billion ≈ $30.70 Million	₩4.12 Billion ≈ $2.79 Million	0.091x	+43.12%
2014-12-31	₩43.14 Billion ≈ $29.24 Million	₩2.74 Billion ≈ $1.86 Million	0.063x	-46.57%
2013-12-31	₩41.57 Billion ≈ $28.17 Million	₩4.94 Billion ≈ $3.35 Million	0.119x	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$24.32 Million

₩35.88 Billion KRW

Market Cap Rank

#24570 Global

#1760 in Korea

Share Price

₩4065.00

Change (1 day)

+0.00%

52-Week Range

₩4010.00 - ₩6940.00

All Time High

₩36786.63